Here are four key notes:
1. The JAZZ Band is intended to treat spinal pathologies requiring vertebral fusion surgery.
2. “With its market size and strong pricing, Brazil is a real growth engine on this continent, and this opens the way for additional milestones to be reached,” said Ludovic Lastennet, CEO of Implanet.
3. Implanet also recently received FDA 510(k) regulatory clearance to market the JAZZ Band as usable with other posterior thoraco-lumbar fixation systems.
4. Implant is a medical technology company that manufactures implants for orthopedic surgery and the JAZZ Band implant is its flagship product.
More articles on devices:
Alphatec reports $43M revenue, ‘softer than anticipated’; $160M net loss: 6 key notes
Globus Medical net income jumps 14.8%: 5 things to know
K2M Q3 revenue up 15.5%; net loss at $10.2M: 10 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
